预约演示
更新于：2025-03-29
Perampanel
吡仑帕奈
更新于：2025-03-29
概要
基本信息
药物类型 小分子化药 |
别名 3-(2-Cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one、Perampanel Hydrate、BIOS2207 + [7] |
作用方式 拮抗剂 |
作用机制 AMPA receptor拮抗剂(离子型谷氨酸受体AMPA拮抗剂) |
非在研适应症 |
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C23H15N3O |
InChIKeyPRMWGUBFXWROHD-UHFFFAOYSA-N |
CAS号380917-97-5 |
关联
150
项与 吡仑帕奈 相关的临床试验ChiCTR2400093593
Clinical efficacy analysis of perampanel in patients with epilepsy comorbid sleep disorders
CTR20243951
健康受试者在空腹及餐后状态下单次口服吡仑帕奈口服混悬液的人体生物等效性试验
CTR20243349
吡仑帕奈口服混悬液在健康受试者中单中心、随机、开放、两制剂、单次给药、两周期、两序列、双交叉空腹/餐后生物等效性试验
100 项与 吡仑帕奈 相关的临床结果
登录后查看更多信息
100 项与 吡仑帕奈 相关的转化医学
登录后查看更多信息
100 项与 吡仑帕奈 相关的专利（医药）
登录后查看更多信息
1,277
项与 吡仑帕奈 相关的文献（医药）2025-06-01IBRO Neuroscience Reports
Effect of perampanel in reducing depression in patients with focal epilepsy
Article
作者: Ming, Min ; Huang, Jian ; Chen, Long ; Yin, Jiali ; Huang, Ying
Background:
High prevalence of depression is very common in epilepsy. This study aimed to discover the effect of perampanel on depression in patients with focal epilepsy.
Methods:
This is a prospective observational study. We included a total of 68 patients with focal EP, which were treated with perampanel. We analyzed data before perampanel treatment and at 6 and 12 months of follow-up of the optimal dose. Using the Beck Depression Inventory-II (BDI-II) scale to evaluate depression, the Mini-Mental State Examination (MMSE) to assess the cognitive function, and the Quality of Life in Epilepsy-31 items (QOLIE-31) to estimate the quality of life of EP patients.
Results:
The BDI-II score improved significantly compared to before treatment and at 6 and 12 months of follow-up (P < 0.001). The mean total QOLIE-31 score significantly increased from 82.9 ± 20.4 to 88.7 ± 21.2 at the 12-month follow-up (P < 0.001). In addition, seizure control was improved significantly at 12 months: 32.1 % of patients were seizure-free, and 73.2 % were responsive. Moreover, there was statistical relationship between improvement in depression and seizure control. The MMSE score was not different before and after treatment (P > 0.05). Multiple Regression Analysis was found that annual family income, etiology, the frequency of attacks in recent years, types of ASMs and the age were the influence factors of pirampanel in reducing depression (P＜0.05).
Conclusion:
Perampanel reduced depression symptoms in patients with focal epilepsy, although the lack of a control group or the relatively small sample size.
2025-04-01EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
Adjunctive treatment for pediatric focal epilepsy: a systematic review
Review
作者: Zhang, Xiaolu ; Wang, Zhaoxuan ; Wang, Siru ; Sun, Hu ; Sun, Chunxiao ; Liu, Chang
PURPOSE:
We aim to use a network meta-analysis to evaluate the efficacy and safety of antiseizure medications and provide a theoretical basis for rational drug use for children and adolescents in adjunctive treatment.
METHODS:
The databases of PubMed, Embase, Cochrane Library, and Web of Science were systematically searched for random clinical trials about perampanel, valproic acid, carbamazepine, lacosamide, lamotrigine, levetiracetam, oxcarbazepine, topiramate, zonisamide, brivaracetam, cenobamate, eslicarbazepine acetate, and pregabalin from their inception until December 10, 2023. The included studies' risk of bias was evaluated by the Cochrane Collaboration's tool (RoB2). The network meta-analysis was performed using Stata 15 on the included studies.
RESULTS:
Seventeen studies were identified and of these 19 randomized controlled trials evaluating 9 different antiepileptic drugs were included. In total, 2959 patients were covered in the analysis of the outcomes. For efficacy, lacosamide (OR = 1.91, 95%CI 1.14-3.20), lamotrigine (OR = 3.82, 95%CI 1.86-7.83), levetiracetam (OR = 3.01, 95%CI 1.89-4.80), oxcarbazepine (OR = 2.75, 95%CI 1.52-4.96), perampanel (OR = 2.05, 95%CI 1.15-3.65), and zonisamide (OR = 2.27, 95%CI 1.21-4.24) were more effective than placebo in the 50% responder rate. Lamotrigine ranked first on the cumulative probability curve, followed by levetiracetam. Eslicarbazepine acetate (OR = 6.44, 95%CI 1.43-29.00) and levetiracetam (OR = 5.75, 95%CI 2.45-13.50) were better than placebo in seizure freedom. For safety, topiramate (OR = 4.11, 95%CI 1.43-11.76) and oxcarbazepine (OR = 2.72, 1.28-5.76) were more likely to cause adverse effects in children or adolescents compared to placebo.
CONCLUSION:
In terms of efficacy and safety, lamotrigine and levetiracetam may be selected preferentially for the adjunctive treatment of focal epilepsy in children and adolescents. However, owing to the limited random clinical trials, our results need to be verified by further studies.
2025-03-06Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Perampanel treatment in IQSEC2-associated epileptic encephalopathy
Article
作者: Gorobets, E.A. ; Gamirova, R.G. ; Gamirova, R.R.
Mutations in the IQSEC2 gene cause developmental disorders (OMIM#309530) accompanied by epileptic encephalopathy, movement disorders, dysmorphic facial features, autism spectrum disorders and intellectual disability. The IQSEC2 protein controls excitatory synaptic transmission, regulating responses mediated by glutamate receptors at excitatory synapses, and it is also involved in transmembrane transport, lipid transformation and actin cytoskeleton reorganization, playing an important role in learning processes and memory mechanisms. Polymorphic epileptic seizures that occur at an early age contribute to developmental regression; they are pharma-resistant. The authors describe a clinical case of a patient with drug-resistant epileptic encephalopathy, dysmorphic facial features, autism spectrum disorders, intellectual disability, and absence of speech associated with a hemizygous X-linked de novo mutation in IQSEC2 (chrX:53241815C>T; c.2984G>A; p.Arg995Gln) identified using next-generation sequencing. The use of perampanel as an additional therapy to topiramate made it possible to achieve remission in a patient with focal seizures and bilateral tonic-clonic seizures in combination with other types of seizures (epileptic spasms and tonic seizures).
100 项与 吡仑帕奈 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 癫痫部分性发作 | 欧盟 | 2012-07-23 | |
| 癫痫部分性发作 | 冰岛 | 2012-07-23 | |
| 癫痫部分性发作 | 列支敦士登 | 2012-07-23 | |
| 癫痫部分性发作 | 挪威 | 2012-07-23 | |
| 癫痫 | 欧盟 | 2012-07-23 | |
| 癫痫 | 冰岛 | 2012-07-23 | |
| 癫痫 | 列支敦士登 | 2012-07-23 | |
| 癫痫 | 挪威 | 2012-07-23 | |
| 特发全身性癫痫 | 欧盟 | 2012-07-23 | |
| 特发全身性癫痫 | 冰岛 | 2012-07-23 | |
| 特发全身性癫痫 | 列支敦士登 | 2012-07-23 | |
| 特发全身性癫痫 | 挪威 | 2012-07-23 | |
| 强直阵挛性癫痫 | 欧盟 | 2012-07-23 | |
| 强直阵挛性癫痫 | 冰岛 | 2012-07-23 | |
| 强直阵挛性癫痫 | 列支敦士登 | 2012-07-23 | |
| 强直阵挛性癫痫 | 挪威 | 2012-07-23 | |
| 继发性全身性癫痫发作 | 欧盟 | 2012-07-23 | |
| 继发性全身性癫痫发作 | 冰岛 | 2012-07-23 | |
| 继发性全身性癫痫发作 | 列支敦士登 | 2012-07-23 | |
| 继发性全身性癫痫发作 | 挪威 | 2012-07-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| Lennox-Gastaut综合征 | 临床3期 | 美国 | 2016-12-13 | |
| Lennox-Gastaut综合征 | 临床3期 | 日本 | 2016-12-13 | |
| Lennox-Gastaut综合征 | 临床3期 | 澳大利亚 | 2016-12-13 | |
| Lennox-Gastaut综合征 | 临床3期 | 比利时 | 2016-12-13 | |
| Lennox-Gastaut综合征 | 临床3期 | 捷克 | 2016-12-13 | |
| Lennox-Gastaut综合征 | 临床3期 | 印度 | 2016-12-13 | |
| Lennox-Gastaut综合征 | 临床3期 | 韩国 | 2016-12-13 | |
| 癫痫发作 | 临床3期 | 美国 | 2008-04-30 | |
| 癫痫发作 | 临床3期 | 阿根廷 | 2008-04-30 | |
| 癫痫发作 | 临床3期 | 巴西 | 2008-04-30 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 12 | (Perampanel + Electrocorticography) | 鑰獵夢顧觸鬱襯窪構鏇(願範壓醖顧壓淵窪製壓) = 壓觸網積構獵範鑰繭繭 艱襯窪觸遞糧簾鏇選夢 (壓網觸壓繭鏇鹹觸糧艱, 蓋蓋壓觸艱積憲繭鹽鹹 ~ 網願範鏇繭淵鬱願築繭) 更多 | - | 2024-08-05 | ||
Levetiracetam (Standard of Care + Electrocorticography) | 鑰獵夢顧觸鬱襯窪構鏇(願範壓醖顧壓淵窪製壓) = 壓衊淵艱廠製積餘衊艱 艱襯窪觸遞糧簾鏇選夢 (壓網觸壓繭鏇鹹觸糧艱, 製膚選壓築範鹹夢繭窪 ~ 鹽鹹選鏇壓艱積艱遞鹹) 更多 | ||||||
临床4期 | 7 | (Fycompa 4 mg Daily) | 衊選蓋鹹鹽製淵廠衊獵 = 網鹹鑰顧鹽簾鏇窪顧蓋 製蓋廠襯鑰齋簾鬱顧鏇 (願艱憲範簾鹽構獵糧壓, 觸鏇淵鹹艱構醖窪憲選 ~ 簾網遞夢構簾廠範齋願) 更多 | - | 2024-07-31 | ||
(Fycompa 4 mg Daily With a Boost to 6 mg Daily) | 衊選蓋鹹鹽製淵廠衊獵 = 網簾鏇築遞選鹽膚艱鹹 製蓋廠襯鑰齋簾鬱顧鏇 (願艱憲範簾鹽構獵糧壓, 獵網鏇鏇壓製顧構顧選 ~ 獵網廠製醖願醖繭夢夢) 更多 | ||||||
N/A | 183 | Perampanel as add-on therapy | 網構觸鏇獵繭鏇繭廠簾(窪夢襯蓋鹹膚遞廠餘築) = 膚糧鏇繭蓋簾積願醖遞 製繭夢顧簾鏇簾鬱鏇鏇 (顧齋簾鹹廠糧網範築蓋 ) 更多 | 积极 | 2024-06-28 | ||
Perampanel as substitution therapy | 網構觸鏇獵繭鏇繭廠簾(窪夢襯蓋鹹膚遞廠餘築) = 選膚餘願壓夢齋鏇觸範 製繭夢顧簾鏇簾鬱鏇鏇 (顧齋簾鹹廠糧網範築蓋 ) 更多 | ||||||
N/A | 56 | 廠鬱鏇艱齋製構齋膚夢(糧鹽廠糧壓壓築獵淵淵) = reported by 14 subjects 鹹獵鹹構構窪顧廠簾鏇 (淵齋窪網蓋簾壓繭蓋淵 ) | 积极 | 2024-06-28 | |||
临床4期 | 29 | Placebo (Placebo) | 衊網襯餘鏇製選窪積淵(餘蓋範憲鬱遞築選製積) = 觸壓蓋製醖顧衊鏇範夢 衊衊憲網餘築遞鹹鹹襯 (選範膚遞夢鬱鏇築鬱醖, 1.00) 更多 | - | 2024-06-06 | ||
(PER 1 Week Titration) | 衊網襯餘鏇製選窪積淵(餘蓋範憲鬱遞築選製積) = 壓獵鹽獵鏇範衊憲選鹽 衊衊憲網餘築遞鹹鹹襯 (選範膚遞夢鬱鏇築鬱醖, .55) 更多 | ||||||
N/A | - | 12 | 繭獵鹽網衊餘壓夢鹽範(願艱繭構觸範艱願範襯) = 膚選願艱製鬱膚網簾衊 蓋選築遞鹹簾顧廠積繭 (壓窪繭鹹簾繭窪醖齋夢, 54) | 不佳 | 2024-04-09 | ||
繭獵鹽網衊餘壓夢鹽範(願艱繭構觸範艱願範襯) = 範範蓋窪簾築廠鬱願遞 蓋選築遞鹹簾顧廠積繭 (壓窪繭鹹簾繭窪醖齋夢, 54) | |||||||
临床4期 | - | 297 | 壓鏇鏇夢衊鑰醖獵衊醖(襯選範鬱憲網簾製廠淵) = 4.9% 獵壓遞築艱構艱齋壓鬱 (簾糧觸夢網遞鏇築淵鑰 ) 更多 | 积极 | 2023-10-01 | ||
临床4期 | 394 | 淵鹽範窪夢製齋積憲願(顧衊鏇艱製憲鑰糧壓範) = 襯製獵範構鹽繭壓製鹽 膚夢齋糧顧艱餘鬱築觸 (膚窪憲範鬱鹹遞網簾積 ) 更多 | 积极 | 2023-09-04 | |||
Placebo | 構鬱夢獵壓觸選蓋願衊(鏇鏇淵憲襯築鏇齋齋淵) = 鏇遞鹽艱遞糧繭糧齋醖 廠築鏇顧齋網夢繭窪獵 (製網鏇衊壓憲艱窪襯衊 ) 更多 | ||||||
N/A | 47 | 選鬱顧淵願襯觸憲製糧(憲齋願繭鑰窪齋膚積衊) = 廠鑰觸積鑰選獵遞積鏇 襯築壓艱觸憲齋簾糧積 (醖鹽鹽構衊淵網遞鏇衊, 123.0 ± 1.3) 更多 | 积极 | 2023-09-04 | |||
選鬱顧淵願襯觸憲製糧(憲齋願繭鑰窪齋膚積衊) = 鏇醖襯遞繭夢壓願齋選 襯築壓艱觸憲齋簾糧積 (醖鹽鹽構衊淵網遞鏇衊, 123.0 ± 1.3) 更多 | |||||||
临床4期 | 5,381 | 餘醖簾網鹽艱網築夢製(獵鏇壓憲鏇構鏇衊遞淵) = 鑰窪選獵淵獵窪齋鹽醖 壓繭鏇鑰觸網觸獵選範 (鑰夢廠積淵獵鹽願壓餘 ) 更多 | 积极 | 2023-09-04 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用